Vorinostat in Treating Patients With Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for
their growth. Giving the drug in different ways may kill more cancer cells. This randomized
phase II trial is studying two different schedules of vorinostat to see how well they work in
treating patients with acute myeloid leukemia.